Luis Miguel Bedoya
Overview
Explore the profile of Luis Miguel Bedoya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moya E, Cerrato C, Bedoya L, Guerra J
EJNMMI Radiopharm Chem
. 2024 Sep;
9(1):64.
PMID: 39235521
Background: Radiopharmaceuticals have been considered a special group of medicines in Europe since 1989. The use of radiopharmaceuticals that have marketing authorization should always be the first option in clinical...
2.
Martin-Illana A, Cazorla-Luna R, Notario-Perez F, Bedoya L, Rubio J, Tamayo A, et al.
Int J Pharm
. 2021 May;
602:120665.
PMID: 33933643
In the absence of an effective vaccine, vaginal microbicides are essential for preventing the sexual transmission of HIV to women. Antiretroviral vaginal films have emerged as promising choices, especially those...
3.
Martin-Illana A, Cazorla-Luna R, Notario-Perez F, Ruiz-Caro R, Bedoya L, Veiga-Ochoa M, et al.
Materials (Basel)
. 2020 Aug;
13(16).
PMID: 32784712
The sustained release of an antiretroviral agent to women mucosa has been proved as an excellent strategy to reduce the sexual transmission of HIV. Hybrid micro-mesoporous particles have been synthesized...
4.
Cazorla-Luna R, Martin-Illana A, Notario-Perez F, Bedoya L, Tamayo A, Ruiz-Caro R, et al.
Mar Drugs
. 2020 Jan;
18(1).
PMID: 31936439
Women are still at high risk of contracting the human immunodeficiency virus (HIV) virus due to the lack of protection methods under their control, especially in sub-Saharan countries. Polyelectrolyte multilayer...
5.
Martin-Illana A, Cazorla-Luna R, Notario-Perez F, Bedoya L, Ruiz-Caro R, Veiga M
Eur J Pharm Sci
. 2018 Oct;
127:38-51.
PMID: 30343152
Nowadays, million women live with the human immunodeficiency virus (HIV) worldwide and many of them are dying per year, particularly in Sub-Saharan Africa. The development of systems that can be...
6.
Di Gianvincenzo P, Calvo J, Perez S, Alvarez A, Bedoya L, Alcami J, et al.
Bioconjug Chem
. 2015 Mar;
26(4):755-65.
PMID: 25734507
The third variable region (V3 peptide) of the HIV-1 gp120 is a major immunogenic domain of HIV-1. Controlling the formation of the immunologically active conformation is a crucial step to...
7.
Abad M, Bedoya L, Apaza L, Bermejo P
Molecules
. 2012 Mar;
17(3):2542-66.
PMID: 22388966
Numerous members of the Anthemideae tribe are important as cut flowers and ornamental crops, as well as being medicinal and aromatic plants, many of which produce essential oils used in...
8.
Bedoya L, Abad M, Calonge E, Saavedra L, Gutierrez C M, Kouznetsov V, et al.
Antiviral Res
. 2010 Jul;
87(3):338-44.
PMID: 20600334
18 quinoline-based compounds were tested for antiviral properties against human immunodeficiency syndrome (HIV). The compounds tested here contain quinoline or tetrahydroquinoline rings and can be divided into two main groups:...
9.
Di Gianvincenzo P, Marradi M, Martinez-Avila O, Bedoya L, Alcami J, Penades S
Bioorg Med Chem Lett
. 2010 Apr;
20(9):2718-21.
PMID: 20382017
Gold nanoparticles coated with multiple copies of an amphiphilic sulfate-ended ligand are able to bind the HIV envelope glycoprotein gp120 as measured by surface plasmon resonance (SPR) and inhibit in...
10.
Abad M, Bedoya L, Bermejo P
Curr Drug Metab
. 2010 Apr;
11(2):171-81.
PMID: 20359286
Medicinal plants are gaining in popularity due to the various advantages they offer, such as fewer side-effects, better patient compliance, relatively low cost and high accessibility as well as their...